Prices are updated after-hours


Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date

tags : Treatment    save search

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
Published: 2022-06-27 (Crawled : 23:00) - biospace.com/
KZR | News M | $5.78 -4.31% -0.17% | twitter stocktwits trandingview |
Health Technology
| | O: -1.99% H: 2.96% C: -2.36%

treatment sciences for topline lupus life trial positive results
Cancer Gene Therapy Market to Grow at 10.1% through 2032, Amid High Adoption in Breast Cancer Treatment - Future Market Insights, Inc.
Published: 2022-06-27 (Crawled : 15:20) - prnewswire.com
CRNX | News A | $18.59 -5.2% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.66% H: 1.22% C: -5.83%
AZN | News | $66.465 -0.65% -0.42% | twitter stocktwits trandingview |
Health Technology
| | O: -0.36% H: 1.22% C: 0.38%
ADAP | News S | $1.71 5.56% 3.09% | twitter stocktwits trandingview |
Health Technology
| | O: 1.85% H: 6.67% C: 3.03%
AZNCF | News | $129.21 | twitter stocktwits trandingview |
Health Technology
| | O: -1.55% H: 4.43% C: 0.03%
NVS | News | $85.28 0.53% 0.02% | twitter stocktwits trandingview |
Health Technology
| | O: 1.86% H: 1.05% C: 0.24%
GSK | News | $43.7 0.02% 0.05% | twitter stocktwits trandingview |
Health Technology
| | O: -0.16% H: 0.61% C: 0.18%
GLAXF | News | $21.1 | twitter stocktwits trandingview |
Health Technology
| | O: 0.47% H: 3.73% C: 3.73%
AMGN | News | $244.89 -0.2% -0.56% | twitter stocktwits trandingview |
Health Technology
| | O: -0.08% H: 0.45% C: -0.13%

treatment therapy cancer market
National Organization for Rare Disorders (NORD) honors NULIBRY® (fosdenopterin) for the Treatment of molybdenum cofactor deficiency (MoCD) Type A with 2022 Industry Innovation Award
Published: 2022-06-27 (Crawled : 15:00) - biospace.com/
BBIO | News A | $9.34 1.08% -0.43% | twitter stocktwits trandingview |
Health Technology
| | O: 0.22% H: 2.22% C: 1.3%

nulibry treatment rare for innovation
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
Published: 2022-06-27 (Crawled : 13:20) - biospace.com/
ACER | News A | $1.42 16.39% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 1.64% H: 29.84% C: 15.32%

treatment for trial therapeutics
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
CYBN | News | $0.615 4.7% 0.81% | twitter stocktwits trandingview |
n/a
| | O: 0.44% H: 8.47% C: 4.24%

cyb003 treatment fda clearance for trial potential
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
PHGE | News | $0.733 4.73% -0.41% | twitter stocktwits trandingview |
Health Technology
| | O: -1.41% H: 7.23% C: 5.8%

bx004 treatment fibrosis for respiratory infections
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
MRK | News | $94.41 1.37% 0.27% | twitter stocktwits trandingview |
Health Technology
| | O: -0.16% H: 2.7% C: 1.3%
FNCTF | News | $11.38 | twitter stocktwits trandingview |
Communications
| | O: 0.62% H: 0.0% C: -0.35%

lynparza treatment for chmp positive cancer
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-06-27 (Crawled : 07:00) - prnewswire.com
ABBV | News | $153.14 0.53% 0.04% | twitter stocktwits trandingview |
Health Technology
| | O: 1.5% H: 1.6% C: 0.09%

rinvoq treatment active for chmp approval
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2022-06-27 (Crawled : 01:00) - prnewswire.com
LLY | News S | $327.27 0.51% 0.04% | twitter stocktwits trandingview |
Health Technology
| | O: 1.52% H: 2.04% C: 0.94%
INCY | News | $77.36 -1.06% -0.26% | twitter stocktwits trandingview |
Health Technology
| | O: 3.36% H: 0.35% C: -0.71%

tyvyt treatment approval china
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Published: 2022-06-25 (Crawled : 16:20) - prnewswire.com
IONS | $39.35 0.26% 0.0% | twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

treatment hepatitis liver for presentation positive international
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
Published: 2022-06-24 (Crawled : 20:00) - biospace.com/
BMY | News | $79.98 1.29% 0.34% | twitter stocktwits trandingview |
Health Technology
| | O: 1.2% H: 0.0% C: 0.0%

treatment sclerosis
Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights
Published: 2022-06-24 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $16.205 | twitter stocktwits trandingview |
Manufacturing
| | O: 4.33% H: 0.0% C: -2.44%
ALPMF | News | $15.83 | twitter stocktwits trandingview |
Health Technology
| | O: 0.99% H: 0.0% C: -0.5%
ABBV | News | $153.14 0.53% 0.04% | twitter stocktwits trandingview |
Health Technology
| | O: 1.57% H: 0.0% C: 0.0%
BHC A | $8.68 -0.8% 0.35% | twitter stocktwits trandingview |
Health Technology
| | O: 5.78% H: 13.91% C: 13.78%
IRWD | $11.59 2.57% 0.18% | twitter stocktwits trandingview |
Health Technology
| | O: 0.27% H: 2.08% C: 1.99%
TAK | News | $14.06 1.59% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.36% H: 0.0% C: 0.0%
NVS | News | $85.28 0.53% 0.02% | twitter stocktwits trandingview |
Health Technology
| | O: 2.38% H: 0.0% C: 0.0%

treatment market
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR)
Published: 2022-06-24 (Crawled : 12:00) - biospace.com/
SNY | News | $52.62 -1.5% -0.41% | twitter stocktwits trandingview |
Health Technology
| | O: 3.49% H: 0.0% C: 0.0%
NTLA | $53.43 0.04% -0.02% | twitter stocktwits trandingview |
Health Technology
| | O: 13.34% H: 5.18% C: 1.71%
REGN | $602.68 -1.6% 0.15% | twitter stocktwits trandingview |
Health Technology
| | O: 3.08% H: 0.18% C: 0.07%

ntla-2001 treatment for
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
Published: 2022-06-24 (Crawled : 12:00) - biospace.com/
MRK | News | $94.41 1.37% 0.27% | twitter stocktwits trandingview |
Health Technology
| | O: 3.84% H: 0.0% C: 0.0%

keytruda treatment melanoma for
Psoriasis Treatment Market Players Observe Rising Trend of Personalized Medicines, According to TMR Report
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
AZN | News | $66.465 -0.65% -0.42% | twitter stocktwits trandingview |
Health Technology
| | O: 4.41% H: 0.0% C: 0.0%
JNJ | News | $182.12 -0.09% 0.1% | twitter stocktwits trandingview |
Health Technology
| | O: 1.94% H: 0.0% C: 0.0%
PFE | News | $51.88 0.56% 0.04% | twitter stocktwits trandingview |
Health Technology
| | O: 2.96% H: 0.0% C: 0.0%
AZNCF | News | $129.21 | twitter stocktwits trandingview |
Health Technology
| | O: 0.64% H: 4.18% C: 1.33%
NVS | News | $85.28 0.53% 0.02% | twitter stocktwits trandingview |
Health Technology
| | O: 2.38% H: 0.0% C: 0.0%
LLY | News S | $327.27 0.51% 0.04% | twitter stocktwits trandingview |
Health Technology
| | O: 3.32% H: 0.0% C: 0.0%

treatment report psoriasis market
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
NVS | News | $85.28 0.53% 0.02% | twitter stocktwits trandingview |
Health Technology
| | O: 2.38% H: 0.0% C: 0.0%

scemblix treatment for chmp novartis leukemia positive
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
NTLA | $53.43 0.04% -0.02% | twitter stocktwits trandingview |
Health Technology
| | O: 13.34% H: 5.18% C: 1.71%
SNY | News | $52.62 -1.5% -0.41% | twitter stocktwits trandingview |
Health Technology
| | O: 3.49% H: 0.0% C: 0.0%
REGN | $602.68 -1.6% 0.15% | twitter stocktwits trandingview |
Health Technology
| | O: 3.08% H: 0.18% C: 0.07%

ntla-2001 treatment for
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
Published: 2022-06-24 (Crawled : 06:00) - globenewswire.com
ARGX | $374.17 2.7% -0.1% | twitter stocktwits trandingview |
Health Technology
| | O: 2.55% H: 0.65% C: 0.52%

treatment europe for chmp positive
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Published: 2022-06-23 (Crawled : 16:00) - biospace.com/
GILD | $62.84 -0.38% -0.13% | twitter stocktwits trandingview |
Health Technology
| | O: 0.5% H: 0.0% C: 0.0%

hepcludex treatment hepatitis virus response
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
CNSP | $0.2611 -1.4% 4.61% | twitter stocktwits trandingview |
Health Technology
| | O: 32.07% H: 1.89% C: -24.85%
RETA | $32.88 5.79% 4.99% | twitter stocktwits trandingview |
Health Technology
| | O: -0.09% H: 3.99% C: 3.0%

treatment fda ongoing for trial approval berubicin
Your saved searches
Save your searches and get alerts when important news are released.

Mentioned Today
ABBV | News | $153.14 0.53% 0.04% | twitter stocktwits trandingview |
Health Technology

BNPQF | News | $50.78 | twitter stocktwits trandingview |
Finance

BNPQY | News | $25.46 | twitter stocktwits trandingview |
Finance and Insurance

BNPZY | News | $ 0% | twitter stocktwits trandingview |
Finance and Insurance

CNXC | News | $147.67 1.63% -0.04% | twitter stocktwits trandingview |
Information

CNXCV | News | $2.27 0% | twitter stocktwits trandingview |
Commercial Services

DMYD | News | $16.21 0% | twitter stocktwits trandingview |
Finance

DMYT | News | $22.76 0% | twitter stocktwits trandingview |
Finance

DRE | News | $56.17 -2.23% 0.0% | twitter stocktwits trandingview |
Finance

EPZM | News | $1.47 54.09% 7.97% | twitter stocktwits trandingview |
Health Technology

FTRP | News | $0.81 1.25% 0.0% | twitter stocktwits trandingview |
Health Care and Social Assistan...

HR | News | $27.23 1.38% 0.0% | twitter stocktwits trandingview |
Finance

HTA | News | $27.7 -0.22% 0.0% | twitter stocktwits trandingview |
Finance

IONQ | News | $4.83 -5.48% 2.07% | twitter stocktwits trandingview |
Professional, Scientific, and T...

LLY | News 4 | $327.27 0.51% 0.04% | twitter stocktwits trandingview |
Health Technology

OMC | News | $64.75 0.23% 0.0% | twitter stocktwits trandingview |
Commercial Services

PACB | News | $5.3 -5.53% -1.78% | twitter stocktwits trandingview |
Health Technology

PLD | News | $120.21 -1.94% 0.54% | twitter stocktwits trandingview |
Finance

PSORF | News | $9.55 0% | twitter stocktwits trandingview |
Consumer Services

RDUS | News | $10.205 0.94% -0.4% | twitter stocktwits trandingview |
Health Technology

SNY | News | $52.62 -1.5% -0.41% | twitter stocktwits trandingview |
Health Technology

SNYNF | News | $104.5 | twitter stocktwits trandingview |
Health Technology

SREV | News | $1.45 -2.76% | twitter stocktwits trandingview |
Technology Services

TUP | News 4 | $7.16 1.42% 0.0% | twitter stocktwits trandingview |
Producer Manufacturing

USAK | News | $30.85 -0.48% -0.39% | twitter stocktwits trandingview |
Transportation

WWE | News | $61.0 0.63% 0.0% | twitter stocktwits trandingview |
Consumer Services

ZEN | News | $74.65 0.65% -0.07% | twitter stocktwits trandingview |
Technology Services